Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

More On SAZ.DE



News & Info


Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates
  • Research Reports


  • Major Holders
  • Insider Transactions
  • Insider Roster


Stada-Arzneimittel AG (SAZ.DE)

29.13 Up 0.05(0.15%) Apr 17, 11:35AM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Stada-Arzneimittel AG
Stadastrasse 2-18
Bad Vilbel, 61118
Germany - Map
Phone: 49 6101 6030
Fax: 49 6101 603 259

Index Membership:N/A
Industry:Drugs - Generic
Full Time Employees:9,825

Business Summary 

STADA Arzneimittel Aktiengesellschaft is engaged in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates primarily in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s primarily products include Phospholipide, a liver medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Enalapril, an ACE inhibitor; and Omeprazole, a stomach medicine. The Branded Products segment provides non-prescription products. This segment’s primarily products comprise Grippostad, a cold medicine; Apo-Go, a Parkinson medicine; Snup, a nasal preparation; Zaldiar, a pain medicine; Chondroxid for the treatment of degenerative joint diseases; and Ladival, a sun cream. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for two monoclonal antibodies rituximab and optionally trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Stada-Arzneimittel AG

Key Executives 
Mr. Hartmut Retzlaff , 61
Chairman of the Exec. Board and Chief Exec. Officer of the Exec. Board
Mr. Helmut Kraft , 55
Chief Financial Officer and Member of Exec. Board
Dr. Matthias Wiedenfels , 41
Chief Bus. Devel. & Central Services Officer and Member of Exec. Board
Mr. Ulf Pangratz , 49
VP for Branded Products and Chief Exec. Officer of Stada Arzneimittel Austrian unit
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in EUR.